The Foundation was established with the vision that focused ultrasound would improve the quality of life and decrease the cost of care for millions of patients.
2016 was our most successful year, and as a result we see this vision coming closer to reality. The dialogue has shifted from if focused ultrasound can become a mainstream standard of care to when it will.
The number and diversity of mechanisms by which focused ultrasound affects tissue are expanding, creating the possibility to treat an even wider variety of medical disorders. Indications currently in research, development, and commercialization have skyrocketed to more than 75 from just a handful a decade ago. The number of research sites, investigators, regulatory approvals, commercial treatment sites, and patients treated all show impressive growth.
The 2017 State of the Field Report includes new charts, graphs, and timelines not in previous versions. These additions present a longitudinal view of how the field has grown over time, further demonstrating its impressive trajectory.
Read this report to find out more about the:
Increasing number of research sites and regulatory approvals
Dramatic upswing in first-in-human treatments
Two indications dominating patient treatments worldwide
The number of indications has doubled in the last five years with an overall shift toward clinical research and regulatory approval. At the time of the report, there were more than 75 indications in various stages of research, and more have been identified in the weeks since.
State of Research and Regulatory Approval by Indication
Focused ultrasound was first conceptualized in 1950, but clinicians abandoned the technique due to a lack of imaging capabilities. First-in-human treatments using focused ultrasound have exploded in the past decade, and we expect to see the numbers continue to grow.
Nearly 168,000 focused ultrasound treatments have been performed worldwide;* the vast majority of which have been for uterine fibroids and prostate diseases. Though brain treatments make up only a small portion of the total, the range of brain conditions treated is indicative of where the field is headed.
Twenty-two conditions currently have regulatory approval by various agencies around the world, and that number has increased dramatically in the last decade. Regionally, Europe and Asia top the list.
We use cookies to optimize our website and our service.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
By using FUSF’s AI agent, you acknowledge and agree that your use is governed by FUSF’s Terms of Use Agreement. If you do not agree to be bound by the Terms of Use Agreement, you may not access or use FUSF’s AI agent.
